Press Releases

Company News
Jan 02, 2020
PALATINE, Ill. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today provided an update on its development of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets using Acura’s LIMITx™ technology intended to mitigate risks associated with overdose of the
Oct 01, 2019
PALATINE, Ill. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced,
Sep 16, 2019
PALATINE, Ill. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. , a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and product candidates intended to mitigate the risk of outcomes associated with product misuse announced
Sep 09, 2019
PALATINE, Ill. , Sept. 09, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR), today announced that it has engaged Catalent Pharma Solutions, LLC (“Catalent”) to initiate manufacturing scale-up of LTX-03 (Hydrocodone Bitartrate and Acetaminophen) Tablets to ultimately be used in
Jul 02, 2019
Agreement Provides For Completion of Development and Commercialization Transaction Valued at up to $21.3 Million , not including Royalties PALATINE, Ill. , July 02, 2019 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC Pink: ACUR) today announced a License, Development and Commercialization
Nov 27, 2018
PALATINE, Ill. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2018 .
Oct 09, 2018
PALATINE, Ill. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR) , a specialty pharmaceutical company focused on innovating abuse deterrent drugs , today announced that on October 5, 2018 we restructured our debt obligations by (a) receiving an additional $1.8 million
Aug 14, 2018

PALATINE, Ill. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018 . The Company reported a net loss of $2.8 million or

Jun 29, 2018

PALATINE, Ill. , June 29, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three months ended March 31, 2018 . The Company reported for the first quarter 2018 a net

Jun 07, 2018

PALATINE, Ill. , June 07, 2018 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTC PINK:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and twelve months ended December 31, 2017 .

Nov 13, 2017
PALATINE, Ill. , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017 .
Oct 09, 2017
PALATINE, Ill. , Oct. 09, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that topline results from clinical study AP-LTX-300 (Study 300) for its LIMITx™ oral abuse deterrent drug LTX-03
Sep 11, 2017
PALATINE, Ill. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced the results from the previously undisclosed exploratory arm of its second LIMITx™ clinical study, study
Aug 31, 2017
PALATINE, Ill. , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that Bob Jones , President and Chief Executive Officer, will present at the 19 th Annual Rodman & Renshaw Global
Aug 14, 2017
PALATINE, Ill. , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2017 . The Company reported a net loss of $2.15 million or
Aug 03, 2017
PALATINE, Ill. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for the second quarter 2017 following the close of financial markets
Jul 24, 2017

*** Provides Funding to Advance Development of Products Utilizing LIMITx™ Technology ***